Evaxion Biotech A/s Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.99% in Evaxion Biotech A/S as of March 31, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 9.99% in Evaxion Biotech A/S, holding 639,329 American Depositary Shares as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Merck & Co. Affirms Nearly 20% Stake in Evaxion Biotech A/S Through Subsidiary Holdings
Merck & Co., through its indirect wholly-owned subsidiary Merck Global Health Innovation Fund, LLC, has reported a beneficial ownership of 19.96% in Evaxion Biotech A/S, comprising ordinary shares and warrants.